CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease

Shinichi Somada, Hiromi Muta, Kazuhiko Nakamura, Xun Sun, Kuniomi Honda, Eikichi Ihara, Hirotada Akiho, Ryoichi Takayanagi, Yasunobu Yoshikai, Eckhard R. Podack, Kenzaburo Tani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Aims Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage. This study investigated the role of CD30 ligand (CD30L)/CD30 signals in intestinal mucosal damage. Methods Serum sCD30 in patients with ulcerative colitis (UC) and Crohn's disease (CD) and healthy individuals was assessed. A model of enteritis induced by anti-CD3 monoclonal antibody injection was studied in wild-type mice and in CD30L knockout mice. Results Increased sCD30 was observed in UC and CD patients, and the level was correlated with disease activity in both conditions. In a murine model of enteritis, histological intestinal damage was significantly reduced in CD30L knockout mice with decreased Th1 and Th17 cytokine levels. Moreover, blocking of CD30L/CD30 signals by CD30-immunoglobulin (CD30-Ig) resulted in reduced inflammation. Conclusions Increased sCD30 expression correlating with disease activity suggested that CD30L/CD30 signals play an important role in pathogenesis of UC and CD. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model. Successful blockade of enteritis by CD30-Ig suggests a potential tool for future therapy of inflammatory bowel diseases.

Original languageEnglish
Pages (from-to)2031-2037
Number of pages7
JournalDigestive Diseases and Sciences
Volume57
Issue number8
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

CD30 Ligand
Inflammatory Bowel Diseases
Enteritis
Ulcerative Colitis
Crohn Disease
Knockout Mice
Immunoglobulins
Lymphoma
B-Lymphocytes
Monoclonal Antibodies
Cell Membrane
Cytokines
Inflammation
T-Lymphocytes
Injections

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Physiology

Cite this

CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. / Somada, Shinichi; Muta, Hiromi; Nakamura, Kazuhiko; Sun, Xun; Honda, Kuniomi; Ihara, Eikichi; Akiho, Hirotada; Takayanagi, Ryoichi; Yoshikai, Yasunobu; Podack, Eckhard R.; Tani, Kenzaburo.

In: Digestive Diseases and Sciences, Vol. 57, No. 8, 01.08.2012, p. 2031-2037.

Research output: Contribution to journalArticle

Somada, S, Muta, H, Nakamura, K, Sun, X, Honda, K, Ihara, E, Akiho, H, Takayanagi, R, Yoshikai, Y, Podack, ER & Tani, K 2012, 'CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease', Digestive Diseases and Sciences, vol. 57, no. 8, pp. 2031-2037. https://doi.org/10.1007/s10620-012-2129-0
Somada, Shinichi ; Muta, Hiromi ; Nakamura, Kazuhiko ; Sun, Xun ; Honda, Kuniomi ; Ihara, Eikichi ; Akiho, Hirotada ; Takayanagi, Ryoichi ; Yoshikai, Yasunobu ; Podack, Eckhard R. ; Tani, Kenzaburo. / CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 8. pp. 2031-2037.
@article{6adc36924ddd46698e2e774b8d31e620,
title = "CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease",
abstract = "Background and Aims Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage. This study investigated the role of CD30 ligand (CD30L)/CD30 signals in intestinal mucosal damage. Methods Serum sCD30 in patients with ulcerative colitis (UC) and Crohn's disease (CD) and healthy individuals was assessed. A model of enteritis induced by anti-CD3 monoclonal antibody injection was studied in wild-type mice and in CD30L knockout mice. Results Increased sCD30 was observed in UC and CD patients, and the level was correlated with disease activity in both conditions. In a murine model of enteritis, histological intestinal damage was significantly reduced in CD30L knockout mice with decreased Th1 and Th17 cytokine levels. Moreover, blocking of CD30L/CD30 signals by CD30-immunoglobulin (CD30-Ig) resulted in reduced inflammation. Conclusions Increased sCD30 expression correlating with disease activity suggested that CD30L/CD30 signals play an important role in pathogenesis of UC and CD. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model. Successful blockade of enteritis by CD30-Ig suggests a potential tool for future therapy of inflammatory bowel diseases.",
author = "Shinichi Somada and Hiromi Muta and Kazuhiko Nakamura and Xun Sun and Kuniomi Honda and Eikichi Ihara and Hirotada Akiho and Ryoichi Takayanagi and Yasunobu Yoshikai and Podack, {Eckhard R.} and Kenzaburo Tani",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s10620-012-2129-0",
language = "English",
volume = "57",
pages = "2031--2037",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease

AU - Somada, Shinichi

AU - Muta, Hiromi

AU - Nakamura, Kazuhiko

AU - Sun, Xun

AU - Honda, Kuniomi

AU - Ihara, Eikichi

AU - Akiho, Hirotada

AU - Takayanagi, Ryoichi

AU - Yoshikai, Yasunobu

AU - Podack, Eckhard R.

AU - Tani, Kenzaburo

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background and Aims Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage. This study investigated the role of CD30 ligand (CD30L)/CD30 signals in intestinal mucosal damage. Methods Serum sCD30 in patients with ulcerative colitis (UC) and Crohn's disease (CD) and healthy individuals was assessed. A model of enteritis induced by anti-CD3 monoclonal antibody injection was studied in wild-type mice and in CD30L knockout mice. Results Increased sCD30 was observed in UC and CD patients, and the level was correlated with disease activity in both conditions. In a murine model of enteritis, histological intestinal damage was significantly reduced in CD30L knockout mice with decreased Th1 and Th17 cytokine levels. Moreover, blocking of CD30L/CD30 signals by CD30-immunoglobulin (CD30-Ig) resulted in reduced inflammation. Conclusions Increased sCD30 expression correlating with disease activity suggested that CD30L/CD30 signals play an important role in pathogenesis of UC and CD. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model. Successful blockade of enteritis by CD30-Ig suggests a potential tool for future therapy of inflammatory bowel diseases.

AB - Background and Aims Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage. This study investigated the role of CD30 ligand (CD30L)/CD30 signals in intestinal mucosal damage. Methods Serum sCD30 in patients with ulcerative colitis (UC) and Crohn's disease (CD) and healthy individuals was assessed. A model of enteritis induced by anti-CD3 monoclonal antibody injection was studied in wild-type mice and in CD30L knockout mice. Results Increased sCD30 was observed in UC and CD patients, and the level was correlated with disease activity in both conditions. In a murine model of enteritis, histological intestinal damage was significantly reduced in CD30L knockout mice with decreased Th1 and Th17 cytokine levels. Moreover, blocking of CD30L/CD30 signals by CD30-immunoglobulin (CD30-Ig) resulted in reduced inflammation. Conclusions Increased sCD30 expression correlating with disease activity suggested that CD30L/CD30 signals play an important role in pathogenesis of UC and CD. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model. Successful blockade of enteritis by CD30-Ig suggests a potential tool for future therapy of inflammatory bowel diseases.

UR - http://www.scopus.com/inward/record.url?scp=84866362744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866362744&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2129-0

DO - 10.1007/s10620-012-2129-0

M3 - Article

VL - 57

SP - 2031

EP - 2037

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 8

ER -